Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00426998 · ClinicalTrials.gov registry record · Phase 2
Combination Bevacizumab and Verteporfin (Two Different Sequences of Treatment)in Neovascular AMD
A Phase 2 study of Macular Degeneration and Choroidal Neovascularization, sponsored by Retinal Consultants Medical Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT00426998: Completed Phase 2 study of Macular Degeneration and Choroidal Neovascularization, sponsored by Retinal Consultants Medical Group.
NCT00426998 is a Phase 2 study of Macular Degeneration and Choroidal Neovascularization that has completed, run by Retinal Consultants Medical Group. The registered enrollment target is 30 participants, below the 178-participant average among 26 other Macular Degeneration trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00426998, a Phase 2 study of Macular Degeneration and Choroidal Neovascularization, has completed, sponsored by Retinal Consultants Medical Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to compare different timing therapies of Verteporfin with Bevacizumab to treat choroidal neovascularization (CNV) due to age-related macular degeneration (AMD).
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Verteporfin
Study Locations (1)
California
- Retinal Consultants Medical Group, Inc. - Sacramento
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2006-04 |
| Phase | Phase 2 |
What the finished NCT00426998 record still lists
NCT00426998 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 178-participant average among 26 other Macular Degeneration trials with a reported enrollment target (83% lower).
The record links to 2 conditions, with Macular Degeneration appearing as the primary indexed condition, and to 2 interventions - of which Bevacizumab is the first listed.
NCT00426998 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00426998 about?
NCT00426998 is a clinical study titled "Combination Bevacizumab and Verteporfin (Two Different Sequences of Treatment)in Neovascular AMD". The purpose of this research study is to compare different timing therapies of Verteporfin with Bevacizumab to treat choroidal neovascularization (CNV) due to age-related macular degeneration (AMD).
What is the current status of trial NCT00426998?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2006-04.
What conditions does trial NCT00426998 study?
This clinical trial studies the following conditions: Macular Degeneration, Choroidal Neovascularization.
What interventions are being tested in trial NCT00426998?
The interventions under investigation include: Bevacizumab (DRUG), Verteporfin (DRUG).
Who is sponsoring clinical trial NCT00426998?
This trial is sponsored by Retinal Consultants Medical Group, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00426998 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00426998's enrollment target sits among peer trials
30 19th of 26 higher than 6 of 26 other Macular Degeneration trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Macular Degeneration trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
RECRUITING · Phase 2
-
A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration
COMPLETED · Phase 2
-
Factors in Learning And Plasticity: Macular Degeneration
RECRUITING · NA
-
Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium
RECRUITING · Early Phase 1
-
A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia